![Michael E. Saunders](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Michael E.
Saunders has been Vice President of Clinical Development for Allos Therapeutics, Inc. since November 2004.
Previously, he was Senior Medical Director of Allos Therapeutics from December 2003 to October 2004.
Dr. Saunders was Medical Director of Baxter Hemoglobin Therapeutics, Global Medical Director of BioSurgery and Pharmacovigilance for Baxter BioScience, Senior Director of Clinical Research for Somatogen, Senior Director of Clinical Research and Cardiovascular for Searle and Director of Clinical Research and Cardiovascular for Rhone-Poulenc Rorer.
He received an MD from the University of Kansas School of Medicine.
| Sociétés | Poste | Fin |
|---|---|---|
Allos Therapeutics, Inc.
 Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets anti-cancer therapeutics | Directeur Technique/Scientifique/R&D | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
| Entreprise privées | 2 |
|---|---|
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets anti-cancer therapeutics | Health Technology |
University of Kansas
 University of Kansas Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national
Choisissez Zonebourse 
